Legend Biotech USA Inc.

Contributing Author

Recent Articles by Legend Biotech USA Inc.

Jul-28	Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results LEGN GlobeNewswire
Jul-27	Legend Biotech Announces CEO Transition LEGN -13.28% GlobeNewswire
Jun-17	Legend Biotech Corporation Announces Pricing of Public Offering LEGN -16.68% GlobeNewswire
Jun-17	Legend Biotech Corporation Announces Proposed Public Offering LEGN LEGN -16.68% GlobeNewswire
Jun-15	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma LEGN GlobeNewswire
Jun-14	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma LEGN GlobeNewswire
Jun-02	Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) LEGN +42.22% GlobeNewswire
Jun-01	Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI Data in Multiple Myeloma at ASCO 2026 LEGN -6.08% GlobeNewswire
May-21	Legend Biotech Announces Presentations at ASCO 2026 LEGN GlobeNewswire
May-12	Legend Biotech Reports First Quarter 2026 Results and Recent Highlights LEGN +10.48% GlobeNewswire
May-04	Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth LEGN +12.34% GlobeNewswire
Apr-28	Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results LEGN GlobeNewswire
Mar-10	Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights LEGN GlobeNewswire
Feb-24	Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results LEGN GlobeNewswire
Jan-21	Legend Biotech to Present CARVYKTI Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use LEGN -11.36% GlobeNewswire
Jan-12	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference LEGN GlobeNewswire
Dec-17	Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference LEGN GlobeNewswire
Dec-06	Legend Biotech Highlights New CARVYKTI Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 LEGN GlobeNewswire
Nov-27	Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade LEGN GlobeNewswire
Nov-13	Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia LEGN GlobeNewswire
Nov-12	Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights LEGN GlobeNewswire
Nov-03	Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting LEGN GlobeNewswire
Oct-29	Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results LEGN GlobeNewswire
Aug-26	Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference LEGN GlobeNewswire
Aug-18	Legend Biotech Appoints Carlos Santos as Chief Financial Officer LEGN GlobeNewswire
Aug-11	Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights LEGN GlobeNewswire
Jul-28	Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results LEGN GlobeNewswire
Jun-03	Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI in Multiple Myeloma at 2025 ASCO Annual Meeting LEGN GlobeNewswire
May-22	Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT LEGN GlobeNewswire
May-19	Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting LEGN GlobeNewswire
May-13	Legend Biotech Reports First Quarter 2025 Results and Recent Highlights LEGN GlobeNewswire

Legend Biotech USA Inc.

Recent Articles by Legend Biotech USA Inc.

Upgrade your Finviz experience